The Role Of Maintenance Therapy after SCT

Name: The Role Of Maintenance Therapy after SCT
Start: 2022-08-31T13:00:00-04:00
End: 2022-08-31T14:00:00-04:00

Aug 31, 2022

01:00PM - 02:00PM EDT

Online Event

Overview

Why is maintenance therapy so strongly recommended after a stem cell transplant? How long do physicians wait to give maintenance therapy after the procedure? For how long is the maintenance therapy given? Learn the answers to these questions and more as we meet with Dr. Samuel Rubinstein who will share with us his professional opinion.

Agenda

01:00 PM

Introduction

Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Samuel Rubinstein

01:05 PM

Presentation

Dr. Samuel Rubinstein

Dr. Samuel Rubinstein shares his professional opinion on the role of maintenance therapy after stem cell transplant.

01:35 PM

Questions and Answers

Audience

Type your questions in the chat and we will answer them!

Speakers & Moderators

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Dr. Samuel Rubinstein

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.